| Name | Nivolumab |
| Description | Nivolumab is a monoclonal antibody and is a humanized PD-1 antibody. Nivolumab has anti-tumor activity and is used in the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma, etc. |
| In vitro | METHODS: CD4+ T cells were co-cultured with DC cells for 6 days, treated with Nivolumab (0-1000 nmol/L), and the supernatant was collected on day 5 to measure IFNγ production by ELISA.
RESULTS: In allogeneic MLR, blockade of PD-1 with Nivolumab systematically resulted in titratable enhancement of IFNγ release. [1]
METHODS: Human colon cancer cells HT29, HCT116 and LoVo were treated with Nivolumab (1 µM) and different chemotherapeutic regimens for 72 h. Cell viability was measured by SRB assay.
RESULTS: Nivolumab decreased the efficacy of chemotherapy and increased the IC50 of 5-FU (3.1-fold, 2.2-fold, and 1.9-fold), OXA (2.8-fold, 4.8-fold, and 15.8-fold), and IRI (2.2-fold, 1.7-fold, and 2.9-fold) in HT29, HCT116, and LoVo, respectively. Nivolumab increased the IC50 for CDDP, DOXO, and TAX.[2] |
| In vivo | METHODS: To assay antitumor activity in vivo, Nivolumab (200 µg) was injected intraperitoneally into huNOG or huNOG FcγR-/- mice harboring HSC4, RKO, HCC827, or NCI-H1975 tumors once a week for four weeks.
RESULTS: In huNOG mice, Nivolumab did not inhibit any xenogeneic human tumors, whereas the growth of HSC4, HCC827, and NCI-H1975 (but not RKO) tumors in huNOG FcγR-/- mice was strongly inhibited or even rejected after Nivolumab treatment. In some experiments, tumor growth was enhanced in Nivolumab-treated huNOG mice, such as HCC827.[3] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | PD-L1 | PDL1 | PD-1/PD-L1 | PD1/PDL1 | PD-1 | PD1 | Nivolumab |
| Inhibitors Related | LSD1-IN-24 | PD-1/PD-L1-IN-9 | BMS-1166-n-piperidine-co-n-piperazine dihydrochloride | IMMH 010 maleate | Icariside I | Fraxinellone | Pembrolizumab | LSD1-IN-27 | Acesulfame Potassium | Anti-Mouse PD-1 Antibody (RMP1-14) | Panaxadiol | JQ-1 (carboxylic acid) |
United States
